- Partner Shanghai Miracogen (fully owned by LEPU BIOPHARMA CO., LTD) commences US Phase I/II trial with ADC designed to treat solid tumors
- MRG004A selected for clinical development based on highly competitive efficacy and tolerability in preclinical studies compared to conventional ADC technology
- Over 10 ADCs currently being developed by Synaffix licensees
AMSTERDAM, NETHERLANDS, September 29, 2021 — Synaffix B.V., a biotechnology company focused on commercializing its clinical-stage platform technology for the development of antibody-drug conjugates (ADCs) with best-in-class therapeutic index, today announces that its partner Shanghai Miracogen has commenced a Phase I trial in the US with MRG004A, an ADC designed to treat solid tumors. This is the 3rd ADC built with GlycoConnect™ ADC technology to enter the clinic.